Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2006

View Archived Issues

Genta and Emisphere sign licensing agreement for oral gallium compound

Enrollment completed in phase II solid tumor study of CA4P with chemotherapy

Grip strength measurements improve in BioAstin tendonitis study

Noxxon and Pfizer form Spiegelmer product alliance

Pharming to acquire DNage

Reata advances RTA-402 into clinical testing

Paion begins program for next-generation plasminogen activators

Mimetogen completes Series A financing, new licensing agreement

Bioaccelerate Holdings to change name, spin off subsidiaries

Positive opinion handed down in Europe for Ganfort

Exenatide LAR studied for type 2 diabetes in new study

Opposing trends in Oncophage renal cancer phase III trial

CHMP recommends against approval of Zelnorm for IBS-C in Europe

Phase II data for ALGRX-4975 in hernia repair at odds with other phase II results

New dosages of Risperdal M-TAB now available

Rectogesic completes E.U. mutual recognition procedure

Novel calcium-sensing receptor antagonist promotes PTH release in vivo

Affibody molecules -- a tool for preclinical drug profiling

Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome

Lyrica receives European approval for GAD

Aranesp approved for every-three-week dosing

New treatment options for cancer covered in recent patents

Cubist responds to approvable letter for Cubicin

Data on new chemokine CXC receptor antagonists reported at ACS meeting

Preclinical data on the antidiabetic compound SYR-322 presented

A novel target to improve memory: ghrelin

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...